Edition:
United States

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

3.23USD
12:58pm EDT
Change (% chg)

$-0.01 (-0.46%)
Prev Close
$3.24
Open
$3.28
Day's High
$3.33
Day's Low
$3.22
Volume
2,178
Avg. Vol
3,696
52-wk High
$51.00
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

Essa Pharma Qtrly Loss Per Share Of $0.83
Monday, 14 May 2018 07:15pm EDT 

May 14 (Reuters) - ESSA Pharma Inc ::ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER ENDED MARCH 31, 2018.QTRLY LOSS PER SHARE OF $0.83.  Full Article

Essa Pharma Files For Resale Of 113.9 Mln Common Shares By Selling Shareholders
Tuesday, 6 Mar 2018 05:00pm EST 

March 6 (Reuters) - Essa Pharma Inc ::ESSA PHARMA INC FILES FOR RESALE OF CO'S 113.9 MILLION COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING.  Full Article

Essa Pharma Qtrly Loss Per Share $0.07
Tuesday, 13 Feb 2018 05:00pm EST 

Feb 13 (Reuters) - Essa Pharma Inc ::ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017.ESSA PHARMA INC - QTRLY LOSS PER SHARE $0.07.  Full Article

Essa Says Intends To Issue Up To 125 Mln Common Shares At $0.20 Per Share
Tuesday, 2 Jan 2018 07:45pm EST 

Jan 2 (Reuters) - Essa Pharma Inc ::ESSA ANNOUNCES FILING OF AMENDED AND RESTATED PROSPECTUS SUPPLEMENT AND AN UPDATE TO PREVIOUSLY ANNOUNCED EQUITY OFFERING.ESSA PHARMA - INTENDS TO ISSUE UP TO 125,000,000 COMMON SHARES AT A PRICE OF US$0.20 PER COMMON SHARE FOR AGGREGATE GROSS PROCEEDS OF UP TO US$25 MILLION.  Full Article

Essa Pharma Announces Pricing Of Previously Announced Equity Offering
Wednesday, 13 Dec 2017 08:55am EST 

Dec 13 (Reuters) - Essa Pharma Inc ::ESSA PHARMA ANNOUNCES PRICING OF PREVIOUSLY ANNOUNCED EQUITY OFFERING.ESSA PHARMA INC - ‍ESSA INTENDS TO ISSUE COMMON SHARES IN CAPITAL OF COMPANY AT A PRICE OF US$0.20 PER COMMON SHARE.  Full Article

ESSA Pharma announces overnight marketed equity offering
Tuesday, 12 Dec 2017 05:23pm EST 

Dec 12 (Reuters) - Essa Pharma Inc ::ESSA PHARMA ANNOUNCES OVERNIGHT MARKETED EQUITY OFFERING.ESSA PHARMA - TO USE NET PROCEEDS OF OFFERING PRIMARILY TO CONTINUE ONGOING PRECLINICAL DEVELOPMENT OF CO'S ANITEN COMPOUNDS.  Full Article

Essa Pharma Reports Qtrly Loss Per Share Of $0.07
Monday, 11 Dec 2017 09:21pm EST 

Dec 11 (Reuters) - ESSA Pharma Inc ::ESSA PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2017.QTRLY BASIC AND DILUTED LOSS PER COMMON SHARE $0.07‍​.‍CASH ON HAND AS AT SEPTEMBER 30, 2017 WAS $3.98 MILLION, WITH WORKING CAPITAL OF $1.28 MILLION​.  Full Article

Essa Pharma announces results from the phase 1 clinical trial of EPI-506
Monday, 11 Sep 2017 07:31am EDT 

Sept 11 (Reuters) - Essa Pharma Inc :Essa Pharma announces results from the phase 1 clinical trial of epi-506 for treatment of MCRPC and updates clinical and strategic plans.Confirmed EPI-506 is well-tolerated with a favorable safety profile​.Essa initiates corporate restructuring to refocus research and development efforts​.Makes strategic decision to prioritize Aniten program for MCRPC over further clinical development of epi-506​.Corporate restructuring associated with updated clinical plan expected to lower capex in fiscal 2018 by about $7 million versus fiscal 2017.Anticipates that its current resources are sufficient to support planned operations into fourth calendar quarter of 2017​.Essa will discontinue further clinical development of EPI-506.Will implement a corporate restructuring plan to focus research and development resources on its next-generation Anitens targeting AR-NTD​.  Full Article

ESSA Pharma qtrly loss per share $0.12
Monday, 14 Aug 2017 09:25pm EDT 

Aug 14 (Reuters) - Essa Pharma Inc :ESSA Pharma provides business update and announces financial results for the fiscal third quarter ended June 30, 2017.Qtrly loss per share $0.12.  Full Article

ESSA Pharma provides further update on proposed equity offering
Monday, 24 Jul 2017 07:30am EDT 

July 24 (Reuters) - Essa Pharma Inc :Says additional data is currently being received from higher dose cohorts in Phase 1 clinical trial of EPI-506.Says intends to delay an offering until after that data can be announced from ongoing highest dose cohorts.Says it will provide further updates as they become available.  Full Article

BRIEF-Essa Pharma Qtrly Loss Per Share Of $0.83

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER ENDED MARCH 31, 2018